3 unknown, 1 completed, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 2, Completed 1, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
Follow JKB-122: new trials by email Literature Review of JKB-122 trials Research Report on JKB-122
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) JKB-122, Placebo - Autoimmune Hepatitis | Phase 2 | Unknown | TaiwanJ Pharmaceuticals Co., Ltd | 120 | 2020-11-01 | 2020-09-01 |
| A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule JKB-122 in capsule or tablet form - Autoimmune Hepatitis | Phase 1 | Unknown | TaiwanJ Pharmaceuticals Co., Ltd | 8 | 2020-08-01 | 2020-07-15 |
| A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis Placebo, Dose 1 JKB-122, Dose 2 JKB-122 - Nonalcoholic Steatohepatitis (NASH) With Fibrosis | Phase 2 | Unknown | TaiwanJ Pharmaceuticals Co., Ltd | 300 | 2020-06-30 | 2020-02-13 |
| Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies JKB-122 - Autoimmune Hepatitis | Phase 2 | Completed | TaiwanJ Pharmaceuticals Co., Ltd | 20 | 2016-04-30 | 2020-07-21 |
| Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies JKB-122 5mg, JKB-122 15mg, JKB-122 35mg - Chronic Hepatitis C | Phase 2 | Terminated | TaiwanJ Pharmaceuticals Co., Ltd | 54 | 2014-05-01 | 2020-07-21 |
Hepatitis, Autoimmune (3) · Hepatitis (2) · Hepatitis C, Chronic (1) · Non-alcoholic Fatty Liver Disease (1) · Rare Diseases (1)
TaiwanJ Pharmaceuticals Co., Ltd (5)
Taiwan (1) · United States (1)